A Look At Cooper Companies (COO) Valuation After Launch Of Its Global Sustainability Platform

Cooper Companies (COO) is drawing attention after its CooperVision unit launched the MADE BETTER Promise, a global sustainability platform initially tied to the MyDay daily disposable contact lens family.

See our latest analysis for Cooper Companies.

The share price is currently at US$71.21, with a 1-day share price return of a 0.35% decline and a 90-day share price return of a 14.67% decline. The 1-year total shareholder return of an 8.07% decline and 5-year total shareholder return of a 28.68% decline point to weaker long-term momentum despite sustainability and product initiatives.

If this kind of long-term theme interests you, it could be a good time to broaden your search and check out 31 healthcare AI stocks

With the stock down over the past year and trading below some analyst targets and intrinsic estimates, the key question is whether current weakness signals undervaluation or whether the market is already pricing in future growth drivers.

Most Popular Narrative: 21.8% Undervalued

With Cooper Companies last closing at $71.21 versus a narrative fair value of $91.07, the current price sits well below that modeled estimate.

Free cash flow is poised to inflect higher as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity, with management guiding for approximately $2 billion in free cash flow over the next three years. This improved cash generation, tied to strong cost discipline and revenue momentum, will further benefit shareholders via debt reduction and share repurchases.

Read the complete narrative.

Want to see what sits behind that cash flow story and valuation gap? The narrative leans on steady revenue expansion, firmer margins, and a richer earnings base. Curious which assumptions really move that fair value line and how sensitive they are to small changes? The full breakdown walks through those moving pieces in detail.

Result: Fair Value of $91.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that story can change quickly if MyDay’s rollout stumbles or if ongoing weakness in fertility and Paragard demand continues to drag on CooperSurgical’s contribution.

Find out about the key risks to this Cooper Companies narrative.

Another Angle on Valuation

The narrative and DCF work suggest Cooper Companies looks undervalued, yet the market is pricing the shares at a P/E of 34.6x versus 26.3x for the US Medical Equipment industry, 22.9x for peers, and a fair ratio of 28.4x. That premium raises a simple question: is the market overpaying for the story here?

For a closer look at how current pricing compares to earnings and sector benchmarks, it is worth reviewing See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the story so far pointing to mixed sentiment, this is a good moment to review the full data yourself and decide quickly where you stand. You can start with 3 key rewards.

Looking for more investment ideas?

If you are serious about sharpening your portfolio, do not stop at one stock. Use targeted screeners to spot opportunities before they move out of reach.

• Target potential mispricings by scanning companies that pair quality with attractive valuations using the 58 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with meaningful yields and resilient payout profiles through the 11 dividend fortresses.
• Prioritize resilience by filtering for businesses with robust finances and sensible debt levels using the solid balance sheet and fundamentals stocks screener (41 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com